The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: Low-affinity, uncompetitive antagonism

Current Alzheimer Research

Volumn 2, Issue 2, 2005, Pages 155-165

  Lipton, Stuart A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; DIZOCILPINE; GLUTAMIC ACID; ION CHANNEL; MEMANTINE; MEMBRANE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; BINDING AFFINITY; CALCIUM TRANSPORT; CONFERENCE PAPER; DEMENTIA; DEPRESSION; DRUG TOLERABILITY; GLAUCOMA; HUMAN; MULTIINFARCT DEMENTIA; NERVE CELL NECROSIS; NERVE FUNCTION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SYNAPTIC TRANSMISSION; UNITED STATES;

ALZHEIMER DISEASE; ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NERVOUS SYSTEM DISEASES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 20844460621     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567205053585846     Document Type: Conference Paper

References (72)

1. Lipton SA and Rosenberg PA. Mechanisms of disease: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613-622.
2. Lipton SA and Nicotera P. Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium 1998; 23:165-171.
3. Kemp JA and McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci 2002; 5 Suppl:1039-1042.
4. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM and Whitehead J. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000; 355:1949-1954.
5. Sacco RL, DeRosa JT, Haley EC, Jr., Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG and Thompson JL. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. Jama 2001; 285:1719-1728.
6. Kemp JA, Kew JN and Gill R. IN: Handbook of Experimental Pharmacology. Jonas P and Monyer H eds. Springer, Berlin, 1999: 101:495-527.
7. Seif el Nasr M, Peruche B, Rossberg C, Mennel HD and Krieglstein J. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990; 185:19-24.
8. Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci 1993; 16:527-532.
9. Chen H-SV and Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol (Lond) 1997; 499:27-46.
10. Chen H-SV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE and Lipton SA. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992; 12:4427-4436.
11. Chen H-SV, Wang YF, Rayudu PV, Edgecomb P, Neill JC, Segal MM, Lipton SA and Jensen FE. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 1998; 86:1121-1132.
12. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S and Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348:1333-1341.
13. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ and Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomzed, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834-1839.
14. Lucas DR and Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. Ama Arch Opthalmol 1957; 58:193-201.
15. Olney JW. Glutamate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion. J Neuropathol Exp Neurol 1969; 28:455-474.
16. Olney JW and Ho OL. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature 1970; 227:609-611.
17. Lipton SA. Molecular mechanisms of trauma-induced neuronal degeneration. Curr Opin Neurol Neurosurg 1993; 6:588-596.
18. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P and Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 1995; 92:7162-7166.
19. Dreyer EB, Zhang D and Lipton SA. Transcriptional or translational inhibition blocks low dose NMDA-mediated cell death. Neuroreport 1995; 6:942-944.
20. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ and Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995; 36:774-786.
21. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA and Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci 1996; 37:1618-1624;
22. Dreyer EB and Grosskreutz CL. Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Clin Neurosci 1997; 4:270-273.
23. Dreyer EB and Lipton SA. New perspectives on glaucoma. JAMA 1999; 281:306-308.
24. Naskar R, Vorwerk CK and Dreyer EB. Saving the nerve from glaucoma: memantine to caspaces. Semin Ophthalmol 1999; 14:152-158.
25. 2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J Neurochem 1992; 59:1211-1220.
26. Rogawski MA and Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003; 9:275-308.
27. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81:741-766.
28. Wu J, Anwyl R and Rowan MJ. beta-Amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. Eur J Pharmacol 1995; 284:R1-3.
29. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I and Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12:376-389.
30. Koh JY, Yang LL and Cotman CW. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 1990; 533:315-320.
31. Topper R, Gehrmann J, Banati R, Schwarz M, Block F, Noth J and Kreutzberg GW. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol (Berl) 1995; 89:23-28.
32. Harkany T, Abraham I, Timmerman W, Laskay G, Totli B, Sasvari M, Konya C, Sebens JB, Korf J, Nyakas C, Zarandi M, Soos K, Penke B and Luiten PG. beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000; 12:2735-2745.
33. Couratier P, Lesort M, Sindou P, Esclaire F, Yardin C and Hugon J. Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol Chem Neuropathol 1996; 27:259-273.
34. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R and Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002; 958:210-221.
35. Tanila H, Minkevicine R and Banjeree P. Behavioral effects of subchronic memantine treatment in APP/PS1 double mutant mice modeling Alzheimer's disease. J Neurochem 2003; 85(Suppl 1):42.
36. Iqbal K, Li L, Sengupta A and Grundke-Iqbal I. Memantine restores okadaic acid-induced changes in protein phosphatase-2A, CAMKII and tau hyperphosphorylation in rat. J Neurochem 2003; 85(Suppl 1):42.
37. Dawson VL, Dawson TM, London ED, Bredt DS and Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A 1991; 88:6368-6371.
38. Dawson VL, Dawson TM, Bartley DA, Uhl GR and Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci 1993; 13:2651-2661.
39. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen H-SV, Sucher NJ, Loscalzo J, Singel DJ and Stamler JS. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364:626-632.
40. Tenneti L, D'Emilia DM, Troy CM and Lipton SA. Role of caspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem 1998; 71:946-959.
41. Yun HY, Gonzalez-Zulueta M, Dawson VL and Dawson TM. Nitric oxide mediates N-methyl-D-aspartate receptor-induced activation of p21ras. Proc Natl Acad Sci U S A 1998; 95:5773-5778.
42. Budd SL, Tenneti L, Lishnak T and Lipton SA. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proc Natl Acad Sci U S A 2000; 97:6161-6166.
43. Okamoto S, Li Z, Ju C, Scholzke MN, Mathews E, Cui J, Salvesen GS, Bossy-Wetzel E and Lipton SA. Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. Proc Natl Acad Sci U S A 2002, 99:3974-3979.
44. Johnson JW and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325:529-531.
45. McBain CJ and Mayer ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994; 74:723-760.
46. Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A and Bankston LA. Cysteine regulation of protein function-as exemplified by NMDA-receptor modulation. Trends Neurosci 2002; 25:474-480.
47. Koroshetz WJ and Moskowitz MA. Emerging treatments for stroke in humans. Trends Pharmacol Sci 1996; 17:227-233.
48. Hickenbottom SL and Grotta J. Neuroprotective therapy. Semin Neurol 1998; 18:485-492.
49. Lutsep HL and Clark WM. Neuroprotection in acute ischaemic stroke. Current status and future potential. Drugs R D 1999; 1:3-8.
50. Rogawski MA. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids 2000; 19:133-149.
51. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001; 2:241-271.
52. Chen H-SV, Rastogi M and Lipton SA. Q/R/N site mutations in the M2 region of NMDAR1/NMDAR2A receptors reveal a non-specific site for memantine action. Soc Neurosci Abstr 1998; 24:342.
53. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989; 166:591-592.
54. Blanpied TA, Boeckman FA, Aizenman E and Johnson JW. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 1997; 77:309-323.
55. Sobolevsky AI, Koshelev SG and Khodorov BI. Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. J Physiol (Lond) 1998; 512:47-60.
56. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W and Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and NIE-115 cell systems in a non-competitive manner. Neurosci Lett 2001; 306:81-84.
57. Reiser G, Binmoller FJ and Koch R. Memantine (1-amino-3,5- dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Res 1988; 443:338-344.
58. Parsons CG, Danysz W and Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999; 38:735-767.
59. Lipton SA. Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology 1992; 42:1403-1405.
60. Pellegrini JW and Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993; 33:403-407.
61. Sucher NJ, Lipton SA and Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res 1997; 37:3483-3493.
62. Osborne NN. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis Neurosci 1999; 16:45-52.
63. Winblad B and Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14:135-146.
64. Lipton SA and Wang YF. NO-related species can protect from focal cerebral ischemia/reperfusion. IN: Pharmacology of Cerebral Ischemia. Krieglstein J and Oberpichler-Schwenk H eds. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1996; 183-191.
65. Zurakowski D, Vorwerk CK, Gorla M, Kanellopoulos AJ, Chaturvedi N, Grosskreutz CL, Lipton SA and Dreyer EB. Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors. Vision Res 1998; 38:1489-1494.
66. Lipton SA, Rayudu PV, Choi YB, Sucher NJ and Chen H-SV. Redox modulation of the NMDA receptor by NO-related species. IN: Progr Brain Res. Mize V, Dawson TM, Dawson M and Friedlander M eds. Elsevier, Amsterdam, 1998; 118:73-82.,
67. Choi YB, Tenneti L, Le DA, Ortiz J, Bai G, Chen H-SV and Lipton SA. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci 2000; 3:15-21.
68. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA and Nicotera P. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995; 15:961-973.
69. Le DA and Lipton SA. Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 2001; 18:717-724.
70. Lipton SA. Concepts: Turning down but not off-Neuroprotection requires a paradigm shift in drug development. Nature 2004; 428:473.
71. Okamoto S-I, Li Z, Ju C, Schölzke MN, Matthews E, Cui J, Salvesen GS, Bossy-Wetzel E, Lipton A. Dominant interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. Proc Natl Acad Sci USA 2002; 99:3974-3979.
72. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324.